The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Support side: New 13D filer — insiders or holders bought while this setup is live; see the timeline.
Radar 84 (high attention) · dilution pressure high · listing risk elevated · governance risk low · runway 1.2 mo · strongest signal: Runway < 6 months (Jun 30, 2026)
What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (runway < 6 months) coexists with live selling machinery (shelf effective, shelf filed). Base case is a discounted raise; the question is when, not if.
An activist has arrived at a company that needs cash — a potential catalyst, but any financing terms may favour the newcomer. A new active >5% holder appeared while the company is under cash or listing pressure - the classic precursor to a recapitalization, board change, or takeover at a discount.
No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 47 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Aug 14, 2026 | · 13D amendment | Schedule 13D/A filed 2026-08-14 filing | 24 |
| Aug 14, 2026 | ▼ Going-concern language | “going concern periodic” language in 10-Q (10-Q) filed 2026-08-14 filing | 16 |
| Aug 12, 2026 | ▼ Shelf effective | EFFECT notice 2026-08-12 filing | 21 |
| Aug 11, 2026 | · 13D amendment | Schedule 13D/A filed 2026-08-11 filing | 24 |
| Aug 6, 2026 | ▼ Unregistered sale | 8-K Item 3.02 filed 2026-08-06 (accepted 16:06 ET) filing | 32 |
| Aug 3, 2026 | ▲ New 13D filer | Schedule 13D filed 2026-08-03 filing | 45 |
| Jul 17, 2026 | ▼ Shelf filed | S-1 filed 2026-07-17 filing | 30 |
| Jul 17, 2026 | ▼ Reverse split | “reverse split” language in DEF 14A (DEF 14A) filed 2026-07-17 filing | 27 |
| Jun 30, 2026 | ▼ Runway < 6 months | ~1.2 months runway: liquidity $2,108,000 as of 2026-06-30, burn $20,869,889/yr (annualized 180-day YTD operating cash flow [companyfacts]) filing | 48 |
| Jun 30, 2026 | ▼ Share count +25% | Shares outstanding 3,200,824 (2026-05-10) -> 22,189,739 (2026-08-13), +593% filing | 45 |
| Jun 30, 2026 | ▼ Near $5M MVLS floor | Public float $4,000,000 (as of 2025-06-30) vs $5M Nasdaq MVLS floor; needs price x shares confirmation filing | 28 |
VIVS VivoSim Labs, INC. · HCWB HCW Biologics Inc. · CYCU Cycurion, Inc. · BIAF bioAffinity Technologies, In · XHLD TEN Holdings, Inc. · VSEE VSEE HEALTH, INC. · screener →